Investment Rating - The report maintains a "Buy" rating for the company [1]. Core Views - The company reported better-than-expected performance in Q4 2024, with a focus on optimizing the supply chain for its plant protection business [5][6]. - The company's revenue for 2024 was 5.68 billion yuan, a decrease of 11.88% year-on-year, but it achieved a net profit of 103 million yuan, marking a return to profitability [5][6]. - The plant protection business experienced a revenue decline due to falling pesticide prices, but gross margins improved due to technological innovation and management optimization [6][7]. - The company is expanding its supply chain layout with a new production base in Malaysia, enhancing its service offerings across the product lifecycle [7]. Summary by Sections Financial Performance - In Q4 2024, the company achieved a revenue of 1.32 billion yuan, down 7.44% year-on-year, but net profit reached 70.64 million yuan, a significant increase of 285% quarter-on-quarter [5]. - For Q1 2025, revenue was 1.51 billion yuan, up 3.02% year-on-year and 14.55% quarter-on-quarter, with a net profit of 49.72 million yuan, reflecting a year-on-year growth of 1747% [5]. Business Segments - The pharmaceutical segment generated 1.29 billion yuan in revenue, down 13.3% year-on-year, but gross margin improved by 13.1 percentage points to 48.0% [6]. - The plant protection segment had a revenue of 3.59 billion yuan, down 15.4% year-on-year, with a gross margin increase of 5.8 percentage points to 20.1% [6]. Future Outlook - The company has revised its profit forecasts for 2025-2027, expecting net profits of 305 million yuan, 415 million yuan, and 536 million yuan respectively, reflecting a positive outlook based on industry recovery and improved margins [8][9]. - The report highlights the company's ongoing projects in the pharmaceutical sector, including six validation projects, with a focus on API and innovative drug intermediates [7][8].

前十大流通股东累计持有： 4905.35万股，累计占流通股比： 55.78%，较上期变化： 18.52万股。 | 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 朱学军 | 2191.27 | 24.92 | 不变 | | 崔小丽 | 921.77 | 10.48 | 不变 | | 朱萌 | 891.59 | 10.14 | 不变 | | 尤卫民 | 251.75 | 2.86 | 不变 | | 董敏 | 141.20 | 1.61 | 17.80 | | 赵贯云 | 128.66 | 1.46 | 37.54 | | 王芳 | 108.17 | 1.23 | 1.78 | | 夏勇 | 98.00 | 1.11 | -22.35 | | 黄剑斌 | 86.93 | 0.99 | 新进 | | 张文泉 | 86.01 | 0.98 | 不变 | | | 较上个报告期退出前十大股东有 | | | | 广发多因子混合 | 103.18 | 1.17 | 退出 | 三、分红送配方案情况 一、主要会计数据和财务指标 | 报告期指标 ...

投资者关系活动记录表 编号：2025-001 投资者关系活 动类别 特定对象调研 分析师会议 媒体采访 业绩说明会 新闻发布会 路演活动 现场参观 其他 参与单位名称 及人员姓名 投资者网上提问 时间 2025 年 4 月 29 日 (周四) 下午 13:00~17:00 地点 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采用 网络远程的方式召开业绩说明会 上市公司接待 人员姓名 1、董事兼副总经理兼董事会秘书王丽 2、财务总监罗梅 3、独立董事陈清胜 4、董事长兼总经理严建林 投资者关系活 动主要内容介 绍 本次投资者关系活动以线上方式进行，公司高管与投资者进行了 沟通交流，主要内容如下： 投资者提出的问题及公司回复情况 公司就投资者在本次说明会中提出的问题进行了回复： 1、股权转让进度 投资者你好，公司实际控制人协议转让股份事宜正在办理过 户登记手续，公司将根据进展情况及时履行信息披露义务， 感谢关注。 2、贵公司和安利股份比较有什么异同，主要优势有哪些 投资者你好，安利股份系公司合成革用聚氨酯材料的潜在客 证券代码：300535 证券简称：达威股份 四川达威科技股份有限公 ...

前十大流通股东累计持有： 8892.86万股，累计占流通股比： 25.8%，较上期变化： -1196.94万股。 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.7300 | 0.8700 | -16.09 | 1.2400 | | 每股净资产（元） | 8.17 | 7.63 | 7.08 | 10.44 | | 每股公积金(元) | 3.34 | 3.54 | -5.65 | 5.58 | | 每股未分配利润(元) | 3.40 | 3.05 | 11.48 | 3.46 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 14.48 | 14.04 | 3.13 | 18.42 | | 净利润(亿元) | 2.5 | 2.97 | -15.82 | 4.24 | | 净资产收益率(%) | 8.96 | 11.62 | -22.89 | 18.71 | 数据四舍五入，查看更多财务数据> ...

2025 年 4 月 29 日 当前价：16.43 元 作者 分析师：赵乃迪 执业证书编号：S0930517050005 010-57378026 zhaond@ebscn.com 分析师：周家诺 执业证书编号：S0930523070007 021-52523675 zhoujianuo@ebscn.com 公司研究 资产减值影响 24Q4 业绩，龙南基地项目陆续投产 ——广信材料（300537.SZ）2024 年报及 2025 一季报点评 增持（维持） 市场数据 | 总股本(亿股) | 2.00 | | --- | --- | | 总市值(亿元)： | 32.93 | | 一年最低/最高(元)： | 14.00/24.83 | | 近 3 月换手率： | 318.54% | 股价相对走势 -10% 11% 33% 54% 75% 04/24 07/24 10/24 01/25 广信材料 沪深300 收益表现 | % | 1M | 3M | 1Y | | --- | --- | --- | --- | | 相对 | -7.50 | -1.26 | 4.03 | | 绝对 | -10.22 | -1.62 | ...

Group 1: Company Operations and Performance - The UK factory's annual capacity utilization rate is increasing, and it is expected to improve its operating conditions in 2025 [1][3] - The Malaysian factory is currently in the construction phase, with future investments dependent on order conditions [1][3] - The company has achieved profitability in the first quarter of 2025 due to exchange gains from the UK subsidiary [2][3] Group 2: Market and Strategic Outlook - The company does not currently plan any mergers or strategic partnerships to overcome market bottlenecks [1] - The company focuses on business expansion, R&D, and project construction to enhance value and protect shareholder interests [2] - The company anticipates steady growth across its business segments in 2025, particularly in plant protection, pharmaceuticals, and functional chemicals [2][3] Group 3: Financial Management and Shareholder Value - The company is implementing a valuation enhancement plan that includes operational improvements, investor relations management, and cash dividends [3] - Measures to manage market volatility and enhance shareholder returns include share buybacks and employee stock ownership plans [3] - The company aims to maintain compliance with environmental regulations while promoting sustainable development [4] Group 4: Environmental and Sustainability Initiatives - The company has been disclosing its sustainability management efforts for four consecutive years and is implementing a greenhouse gas inventory system [3][4] - Future plans include the gradual implementation of carbon reduction strategies to achieve carbon neutrality [4] - All projects are constructed in accordance with environmental protection requirements, ensuring compliance with national regulations [4]

Group 1: Impact of Tariff Policies - The impact of US-China tariff policies on the company's operations is limited, as the export business to the US accounts for a small proportion and most products are on the exemption list [1] - The company has no procurement of raw materials or equipment from the US, and it maintains communication with customers regarding supply chain stability and tax optimization in response to tariff changes [1] Group 2: Financial Performance - In Q1 2025, the company experienced improved operational performance, benefiting from increased foreign exchange gains and a turnaround in derivatives from loss to profit compared to Q1 2024, leading to a significant rise in net profit [1] - The competitive landscape in the new energy sector is intense, with some pressure on performance due to the transition of production lines to fixed assets and depreciation [1] - The company anticipates a breakthrough in revenue from its new energy business in 2025 [2] Group 3: Pharmaceutical Business Development - The pharmaceutical business is progressing as planned, with expectations for growth in 2025, focusing on major clients, primarily European pharmaceutical companies [2] - The company is enhancing existing partnerships while simultaneously developing new clients and strengthening R&D capabilities [2] Group 4: New Energy Business Progress - The new energy business is advancing with ongoing customer communication, project R&D, and quality system development [2] - The company is entering the new energy sector with products like electrolytes, aiming for revenue breakthroughs in 2025 [2] Group 5: Overseas Factory Performance - The UK factory is expected to see improved operational performance in 2025, with a rise in capacity utilization and profitability achieved in Q1 2025 due to foreign exchange gains [3][4] - The Malaysian factory is still in the construction phase, with investment progress contingent on order situations [4]

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Views - The company's civil explosives business demonstrates resilience, with a growth in net profit excluding non-recurring items [6] - The first quarter of 2025 saw a slight decline in revenue but an increase in net profit after excluding non-recurring items, indicating stable performance [8] Financial Performance Summary - The company reported a revenue of 483 million yuan in Q1 2025, a year-on-year decrease of 1.26%, while the net profit attributable to shareholders was 43.08 million yuan, down 8.23% year-on-year [8] - The civil explosives business revenue reached 327 million yuan, a year-on-year increase of 1.40%, with the explosive products revenue at 213 million yuan, down 4.78% [8] - The production of packaged explosives increased by 12.17% year-on-year, while electronic detonators saw a production decrease of 20.27% [8] - The gross margin for Q1 2025 was 32.72%, a slight decrease of 0.5 percentage points year-on-year [8] Earnings Forecast and Valuation - The forecasted net profit attributable to shareholders for 2025 is 318 million yuan, with expected growth rates of 75.86% in 2026 and 42.41% in 2027 [7][9] - The price-to-earnings ratio (P/E) is projected to be 24.66 for 2023, decreasing to 12.86 by 2027 [7][9]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company's Q1 2025 performance met market expectations, with revenue of 2 billion yuan, a year-on-year increase of 32.1% and a quarter-on-quarter decrease of 8.1%. The net profit attributable to shareholders was 230 million yuan, reflecting a year-on-year increase of 39.3% and a quarter-on-quarter decrease of 4.5% [8] - The report anticipates a turning point in fluorochemical and electrolyte segments in 2025, driven by high growth in electrolyte shipments and increasing overseas orders [8] - The company has acquired a 42% stake in Shilei, which is expected to enable self-supply of hexafluoropropylene, meeting 40-50% of its electrolyte demand [8] Financial Forecasts - Total revenue is projected to grow from 7,484 million yuan in 2023 to 16,678 million yuan in 2027, with a compound annual growth rate (CAGR) of approximately 27.95% [1] - Net profit attributable to shareholders is expected to increase from 1,011.07 million yuan in 2023 to 2,005.03 million yuan in 2027, reflecting a CAGR of about 23.97% [1] - The report forecasts earnings per share (EPS) to rise from 1.34 yuan in 2023 to 2.66 yuan in 2027, with a corresponding price-to-earnings (P/E) ratio of 25x for 2025 [1][8]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The refrigerant industry is experiencing a high level of prosperity, with the company's performance expected to continue its strong growth [6] - The profitability of fluoropolymer materials is gradually recovering, driven by increased production and improved market conditions [6] Financial Performance Summary - In 2024, the company achieved operating revenue of 4.61 billion yuan, a year-on-year increase of 5.4%, and a net profit attributable to shareholders of 250 million yuan, up 36.8% year-on-year [4][7] - The company's Q4 2024 results showed operating revenue of 1.23 billion yuan, a year-on-year increase of 7.6%, and a net profit of 105 million yuan, up 385% year-on-year [5] - For Q1 2025, the company reported operating revenue of 1.14 billion yuan, a year-on-year increase of 12.4%, and a net profit of 97 million yuan, up 161.7% year-on-year [10] Product Segment Performance - In the fluorocarbon chemical segment, the company generated revenue of 2.447 billion yuan in 2024, with an average gross margin of 20.37%, up 12.62 percentage points year-on-year [7][9] - The fluoropolymer materials segment achieved revenue of 1.581 billion yuan in 2024, reflecting a year-on-year increase of 17.38% [7][9] - The chemical raw materials segment saw a revenue decline to 436 million yuan in 2024, with a significant drop in average selling price [9] Future Projections - The company is projected to achieve operating revenues of 5.012 billion yuan, 5.433 billion yuan, and 5.853 billion yuan for 2025, 2026, and 2027 respectively, with net profits of 491 million yuan, 589 million yuan, and 680 million yuan [11][13] - The expected price-to-earnings ratios for the next three years are 20, 17, and 15 times [11]